Recent Blog Posts

View Post: CSL Behring: Humate-P packaging, eco-friendly, von Willebrand ...
9 Nov 2009
Humate-P®, Antihemophilic Factor/von Willebrand Factor Complex (Human) Dried, Pasteurized, is a factor replacement therapy with more than 20 years of demonstrated safety and efficacy around the world. After more than one-half billion units ... Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are ...
View Blog: CSL Behring Press Releases - http://www.cslbehring.com/s1/cs/enco/1151443990667/content/115144399...

---

View Post: KOGENATE FS (Antihemophilic Factor VIII) drug information from MPR
27 Oct 2009
August 17, 2009. The FDA has approved Helixate FS (antihemophilic factor VIII [recombinant], from CSL Behring) for routine prophylaxis in children with hemophilia A who are ≤16 years of age and do not have pre-existing joint damage. ... Hematology > Bleeding disorders. Recombinant Human Coagulation Factor VIIa (rFVIIa) 1200mcg, 2400mcg, 4800mcg; per vial; lyophilized pwd for IV inj after reconstitution; preservative-free. ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: FDA Approves New 3000 IU Vial Size for Kogenate FS, antihemophilic ...
7 Aug 2009
Kogenate FS (antihemophilic factor (recombinant)) is used to treat hemophilia A. Includes Kogenate FS side effects, interactions and indications. ... The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases. This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, ...
View Blog: Drugs.com - New Drug Approvals - http://www.drugs.com/newdrugs.html

---

View Post: Recombinate (Antihemophilic Factor (Recombinant)) Drug Information ...
19 Feb 2009
The synthesized rAHF produced by the CHO cells has the same biological effects as Antihemophilic Factor (Human) [AHF (Human)]. Structurally the protein has a similar combination of heterogenous heavy and light chains as found in AHF ...
View Blog: RxList - News and Features - http://www.rxlist.com/script/main/hp.asp

---

View Post: FDA Approves Bayer HealthCare Pharmaceuticals's New 3000 IU Vial ...
7 Aug 2009
7 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved a 3000 IU (international unit) vial size of Kogenate® FS, antihemophilic factor (recombinant). ... The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases. This news release may contain forward-looking statements based on current assumptions and forecasts ...
View Blog: BioSpace.com Featured News and Stories - http://www.biospace.com/

---

View Post: Recombinant Antihemophilic Factor, Xyntha™ Gets FDA Nod For ...
24 Feb 2008 by The MediNEWS Team  
A recombinant antihemophilic factor (Xyntha™ ...
View Blog: http://www.medinewsdirect.com/

---

View Post: New Recombinant XYNTHA Now Available for Patients with He ...
8 Sep 2008
Shipments of the Company's current recombinant factor VIII product, ReFacto(R) Antihemophilic Factor (Recombinant) in the United States will be discontinued as of May 31, 2009. Wyeth anticipates that many patients using ... Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3) 3. Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies 4. STALLERGENES and Protein eXpert Enter ...
View Blog: Latest Biology Technology from Bio-Medicine.Org - http://www.bio-medicine.org/biology-technology-1/

---

View Post: fda approves new 3000 iu vial size for kogenate(r) fs ...
7 Aug 2009 by Rx Times  
kogenate(r) fs, antihemophilic factor (recombinant), is a recombinant factor viii treatment indicated for the control and prevention of bleeding episodes and perioperative management in adults and children (0-16 years) with hemophilia ...
View Blog: Rx Times™ Pharmacy Magazine - Pharmacy... - http://www.rxtimes.com/

---

View Post: Baxter Receives Marketing Approval for ADVATE® in Japan
22 Oct 2006 by Baxter Healthcare  
Baxter developed ADVATE in response to the needs of the hemophilia community, which called for a therapy that would reduce the potential risk of infections that may be caused by pathogens carried in human or animal blood-derived additives. ... RECOMBINATE [Antihemophilic Factor (Recombinant)] is a genetically engineered factor VIII protein indicated for prevention and control of bleeding episodes in people with hemophilia A (classical hemophilia). ...
View Blog: Baxter Corporate Headlines - http://www.baxter.com/

---

View Post: CSL Behring Signs Agreements With Canadian Blood Services and Hema ...
3 Apr 2008 by scidstuff  
the company contracts to supply Helixate(R) FS (Antihemophilic Factor [Recombinant]), Humate(R) P (Antihemophilic factor / von Willebrand Factor Complex [Human], Dried, Pasteurized), Privigen (Immune Globulin Intravenous ...
View Blog: SCID Stuff - http://scidstuff.wordpress.com/

---